Anavex Gets FDA Clearance to Proceed With Fragile X Drug Study
Anavex received FDA clearance to proceed with its blarcamesine IND in Fragile X syndrome and plans a Phase 2a study of about 60 patients.
Anavex received FDA clearance to proceed with its IND for blarcamesine in Fragile X syndrome and plans a Phase 2a study.Key Highlights:Original SEC Filing: ANAVEX LIFE SCIENCES CORP. [ AVXL ] - 8-K - Oct. 15, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider verifying importa…